BridgeBio Pharma Inc - Trending symbols
Latest News of BridgeBio Pharma Inc
Date | Title | Read |
---|---|---|
2025-06-17 12:40 | BridgeBio stock initiated with outperform rating by Wolfe Research | Read |
2025-06-14 22:59 | Alnylam Pharmaceuticals' SWOT analysis: stock poised for growth in expanding ATTR-CM market | Read |
2025-06-14 15:37 | BridgeBio Pharma's SWOT analysis: stock poised for growth amid challenges | Read |
2025-05-23 21:21 | Rocket Cos., Middleby, Diebold Nixdorf, and More Stocks See Action From Activist Investors | Read |
2025-05-20 13:30 | Acoramidis Reduced Incidence of Atrial Fibrillation Events in Patients with ATTR-CM | Read |
2025-05-19 18:33 | Early and Sustained Increase in Serum TTR Levels by Acoramidis Independently Predicted Improved Survival in the ATTRibute-CM Study | Read |
Notifications
Type | Notification | Date |
---|---|---|
RSI Overbought | Overbought RSI (Relative Strength Index) | 2025-06-17 |
Trends
2024-03-31 | 2024-06-30 | 2024-09-30 | 2024-12-31 | 2025-03-31 | ||||||
---|---|---|---|---|---|---|---|---|---|---|
Net Debt | 1,253,420 | 67,903 | 1,321,323 | 142,102 | 1,463,425 | -413,942 | 1,049,483 | -1,579,958 | -530,475 | |
Accumulated Other Comprehensive Income | 63 | -29 | 34 | -3 | 31 | -29 | 2 | -6 | -4 | |
EBIT | -126,163 | -10,415 | -136,578 | -22,753 | -159,331 | -11,483 | -170,814 | 174,557 | 3,743 | |
EBITDA | -117,609 | -17,332 | -134,941 | -22,751 | -157,692 | -11,537 | -169,229 | 174,568 | 5,339 | |
Operating Income | -126,163 | -19,936 | -146,099 | -11,593 | -157,692 | -19,724 | -177,416 | 181,159 | 3,743 | |
Total Other Income Expense Net | -18,382 | 1,813 | -16,569 | 14,514 | -2,055 | -17,252 | -19,307 | 40,331 | 21,024 | |
Income Tax Expense | 8,223 | 7,180 | 15,403 | 18,711 | 34,114 | -14,848 | 19,266 | -20,905 | -1,639 | |
Other Current Liabilities | 113,309 | -24,316 | 88,993 | 31,874 | 120,867 | -23,393 | 97,474 | -109,305 | -11,831 | |
Gross Profit | 890 | 10,445 | 11,335 | -10,989 | 346 | 72,700 | 73,046 | -73,447 | -401 | |
Minority Interest | 5,929 | 875 | 6,804 | -2,248 | 4,556 | -1,144 | 3,412 | -3,439 | -27 |
Comments
How you think about this?